Published in Blood on September 05, 2002
Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A (2006) 3.70
B-lymphocyte-mediated delayed cognitive impairment following stroke. J Neurosci (2015) 2.31
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74
Intraocular lymphoma: update on diagnosis and management. Cancer Control (2004) 1.62
Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol (2013) 1.56
Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs (2014) 1.49
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res (2013) 1.42
Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. Curr Cancer Ther Rev (2011) 1.40
Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol (2009) 1.35
Daclizumab therapy for multiple sclerosis. Neurotherapeutics (2013) 1.33
Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother (2007) 1.30
Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol (2004) 1.29
Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. MAbs (2011) 1.20
How I treat CNS lymphomas. Blood (2013) 1.20
Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma (2008) 1.09
Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology (2011) 1.08
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol (2016) 1.08
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood (2012) 1.07
Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. Neurotherapeutics (2016) 1.02
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol (2008) 1.01
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord (2013) 1.01
Successful treatment of rheumatoid meningitis with cyclophosphamide but not infliximab. Ann Rheum Dis (2006) 0.97
Progress in central nervous system lymphomas. Br J Haematol (2014) 0.96
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Ann Oncol (2013) 0.95
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2009) 0.93
International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future. Ocul Immunol Inflamm (2006) 0.93
Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol (2013) 0.93
Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob Agents Chemother (2010) 0.92
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol (2014) 0.92
Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol (2007) 0.92
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Neurol Neuroimmunol Neuroinflamm (2015) 0.92
Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica (2014) 0.92
Successful Treatment of Posttransplant EBV-Associated Lymphoma and Plasmacytoma Solely Localized to the CNS. Case Rep Hematol (2012) 0.91
Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity. Ann Clin Transl Neurol (2014) 0.89
Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics (2009) 0.88
A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. Yonsei Med J (2009) 0.86
Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. J Clin Invest (2016) 0.85
Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma. Anticancer Drugs (2008) 0.84
Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma. J Cell Mol Med (2014) 0.84
Innovative strategies in lymphoma therapy. Wien Klin Wochenschr (2003) 0.81
Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma. Clin Cancer Res (2011) 0.80
Acute painful lumbosacral paresthesia after intrathecal rituximab. J Neurol (2011) 0.79
Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma. Transl Vis Sci Technol (2012) 0.78
Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab. Oncol Lett (2012) 0.77
Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments. Mult Scler Int (2015) 0.77
Effects of addition of rituximab to chemotherapy on central nervous system events in patients with diffuse large B-cell lymphoma. Mol Clin Oncol (2015) 0.77
Perispinal Delivery of CNS Drugs. CNS Drugs (2016) 0.76
Immune Regulation of Antibody Access to Neuronal Tissues. Trends Mol Med (2017) 0.76
Two Cases of Cerebral Involvement in Malignant Lymphoma (CD20+) That Responded to Combination Therapy with Rituximab and Cladribine. Case Rep Oncol (2012) 0.75
Epstein-Barr virus-associated posttransplant lymphoproliferative disorder involving the central nervous system following autologous hematopoietic stem cell transplantation for neuroblastoma. Springerplus (2014) 0.75
Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy. Oncotarget (2016) 0.75
New approaches in primary central nervous system lymphoma. Chin Clin Oncol (2015) 0.75
Reply to M.C. Chamberlain. J Clin Oncol (2014) 0.75
Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome. Clin Investig (Lond) (2011) 0.75
Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions. Int J Mol Sci (2016) 0.75
It's Time For Combination Therapies: in Multiple Sclerosis. Innov Clin Neurosci (2017) 0.75
Advances in the treatment of newly diagnosed primary central nervous system lymphomas. Blood Res (2017) 0.75
Primary cutaneous marginal zone lymphoma with leptomeningeal involvement and a durable response to rituximab. JAAD Case Rep (2017) 0.75
Pharmacokinetics of an intracerebroventricularly administered antibody in rats. MAbs (2017) 0.75
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature (2011) 5.49
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A (2008) 4.14
PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell (2012) 3.83
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res (2005) 3.07
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol (2012) 2.87
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res (2007) 2.66
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol (2007) 2.64
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 2.53
EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell (2009) 2.50
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Comanagement of surgical patients between neurosurgeons and hospitalists. Arch Intern Med (2010) 2.22
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 2.13
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol (2012) 2.13
Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat (2004) 2.07
Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol (2007) 2.07
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol (2014) 2.04
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.96
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol (2011) 1.92
Clinical presentation of and outcome for solitary rectal ulcer syndrome in children. J Pediatr Gastroenterol Nutr (2012) 1.84
Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol (2006) 1.83
Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol (2005) 1.79
Gene expression and angiotropism in primary CNS lymphoma. Blood (2006) 1.79
Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem (2002) 1.76
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.70
High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res (2006) 1.68
PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol (2005) 1.67
CD36 is important for chylomicron formation and secretion and may mediate cholesterol uptake in the proximal intestine. Gastroenterology (2006) 1.67
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol (2004) 1.66
EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell (2012) 1.65
Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev (2012) 1.64
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood (2006) 1.57
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma (2012) 1.57
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res (2006) 1.52
Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci (2006) 1.52
Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord (2002) 1.48
FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol Cell (2009) 1.47
Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg (2003) 1.47
Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev (2005) 1.44
Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res (2013) 1.42
A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol (2005) 1.41
Failure of cutting balloon angioplasty to prevent restenosis in childhood pulmonary venous stenosis. Catheter Cardiovasc Interv (2006) 1.40
Polymorphisms of DNA repair genes and risk of glioma. Cancer Res (2004) 1.39
Needed in MS: evidence, not EVIDENCE. Neurology (2002) 1.36
Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res (2009) 1.36
The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med (2005) 1.33
The clinical endocrinology workforce: current status and future projections of supply and demand. J Clin Endocrinol Metab (2014) 1.30
Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med (2012) 1.28
Cerebellar volume in offspring from multiplex alcohol dependence families. Biol Psychiatry (2006) 1.27
The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. Am J Epidemiol (2015) 1.27
Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy (2008) 1.27
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol (2012) 1.27
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest (2011) 1.27
Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol (2002) 1.26
Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol (2009) 1.25
Disruption of orbitofrontal cortex laterality in offspring from multiplex alcohol dependence families. Biol Psychiatry (2008) 1.21
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma (2011) 1.21
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol (2005) 1.19
Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation? Am J Physiol Gastrointest Liver Physiol (2007) 1.18
Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol (2010) 1.18
Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro Oncol (2011) 1.16
Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol (2012) 1.16
Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol (2006) 1.15
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol (2015) 1.13
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.13
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J Exp Med (2011) 1.13
Differential gene expression in central nervous system lymphoma. Blood (2009) 1.12
Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg (2005) 1.10
The signature of seeds in resurrection plants: a molecular and physiological comparison of desiccation tolerance in seeds and vegetative tissues. Integr Comp Biol (2005) 1.10
The accuracy of predicting survival in individual patients with cancer. J Neurosurg (2013) 1.08
Identification of a mutation in LARS as a novel cause of infantile hepatopathy. Mol Genet Metab (2012) 1.08
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res (2012) 1.07
The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.07
Psychopathology in offspring from multiplex alcohol dependence families with and without parental alcohol dependence: a prospective study during childhood and adolescence. Psychiatry Res (2008) 1.07
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood (2012) 1.07
Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol (2009) 1.06
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics (2006) 1.06
History of chickenpox and shingles and prevalence of antibodies to varicella-zoster virus and three other herpesviruses among adults with glioma and controls. Am J Epidemiol (2005) 1.05
Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget (2010) 1.05
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.04
Interlaboratory comparison of IDH mutation detection. J Neurooncol (2013) 1.02
The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biol Ther (2006) 1.01
Esophageal strictures during treatment for acute lymphoblastic leukemia. J Pediatr Hematol Oncol (2010) 1.00
Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med (2004) 1.00
fMRI BOLD response to the eyes task in offspring from multiplex alcohol dependence families. Alcohol Clin Exp Res (2007) 0.98